(Information sent by the signatory company)
— First of its kind in the world: The China National Medical Products Administration has approved for clinical trials the multivalent recombinant protein COVID-19 vaccine against XBB variants from WestVac Biopharma/West China Medical Center, Sichuan University
CHENGDU, China, May 20, 2023 /PRNewswire/ — On May 17, 2023, COVID-19 bivalent recombinant protein vaccine (Sf9 cells) and COVID-19 trivalent trimeric recombinant protein vaccine (Sf9 cells) developed by WestVac Biopharma/West China Medical Center, Sichuan University against the latest circulating XBB variants, received “clinical drug trial approval” from the China National Medical Products Administration. These two new vaccines will be rapidly commercialized to protect against the currently circulating XBB variant when the necessary clinical trials are completed. These two vaccines are also the first COVID-19 vaccines in the world to initiate specific clinical trials for variants such as XBB.
The Joint Prevention and Control Mechanism of the State Council held a press conference in early May 2023. The meeting noted that as the inbound and outbound interaction between China and other countries increases, the global impact on the composition of the main pandemic variants of the new coronavirus in my country grew drastically. According to surveillance data[1], the main pandemic variants of the COVID-19 virus in China have evolved into the XBB series. In this context, WestVac Biopharma uses the international advanced insect cell recombinant protein vaccine platform to develop the COVID-19 bivalent recombinant protein vaccine (XBB + prototype strain) (Sf9 cell) Coviccine ® Bivalent and trimetric recombinant protein vaccine COVID-19 trivalent (XBB + BA.5 + Delta variant) (Sf9 cell). WestVac’s two vaccines are crucial for the prevention of current XBB variants and contribute significantly to the ongoing management of the COVID-19 epidemic.
Coviccine® Bivalent– COVID-19 recombinant bivalent protein vaccine (XBB+Prototype) (Célula Sf9)
The COVID-19 Bivalent Recombinant Protein Vaccine (XBB+Prototype) (Sf9 Cell) is an improved version of Coviccine® – Recombinant COVID-19 Vaccine (Sf9 Cell) developed by WestVac Biopharma. Studies have shown that the vaccine induces high titers of neutralizing antibodies against multiple subvariants, including XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1[1] indicating that the vaccine is a universal COVID-19 vaccine effective against multiple strains, especially with a particularly significant increase in neutralizing antibodies against variants of the XBB series.
COVID-19 Trivalent Trimeric Recombinant Protein Vaccine (XBB+BA.5+Delta) (Sf9 Cell)
Taking advantage of the rapid response of the internationally advanced insect cell expression platform in the production of recombinant protein vaccines, WestVac Biopharma and its subsidiary company named WestVac Biopharma (Guangzhou) have constructed the vector for COVID trivalent recombinant protein vaccine. -19 (XBB+BA.5+Delta) (Sf9 cell), and has produced high purity and high quality trivalent recombinant protein vaccines for human use. The vaccine subunit antigen is precisely engineered from the structure of the COVID-19 XBB and BA.5 subvariant S-RBD and HR target proteins and can self-assemble into stable trimeric protein particles. Studies have shown that the vaccine induces high titers of neutralizing antibodies against multiple subvariants, including Omicron XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, BA.2.75 , indicating that it is a broad-spectrum COVID-19 vaccine against multiple subvariants prevalent at home and abroad[1].
Acerca de WestVac Biopharma
WestVac Biopharma Co., Ltd. is an innovative biopharmaceutical company integrating vaccine R&D, production and sales system with an annual production capacity of 1.1 billion vaccine doses. WestVac Biopharma has been successfully selected in the list of unicorn companies from 2021 to 2023. In December 2022, Coviccine® has been approved by the national authority for emergency use, and is on the vaccine procurement list in the process of bidding in more than 20 provinces in China.
Reference:
Photo — https://mma.prnewswire.com/media/2080167/1.jpg
Photo –
View original content:
To read more
2023-05-20 15:02:21
#WestVac #Biopharmas #XBB #Variant #COVID19 #Multivalent #Recombinant #Protein #Vaccine #Forbes #Spain
